Introduction
Chronic heart failure (HF) affects up to 14 million people in Europe.
1 As a syndrome with poor prognosis, HF also has significant influence on patients' well-being and quality of life (QoL). Indeed, HF negatively influences patients' functional capacity and ability to fulfil activities of daily living. As demonstrated in several studies, HF has also significant impact on patients' body composition.
2 -4 Recognized for centuries, it only became clear in 1997 that changes in body composition, as documented by involuntary weight loss, are associated with increased mortality. 5 Muscle wasting, as defined using the criteria of sarcopenia, was shown to be a common co-morbidity of HF, decreasing the functional capacity of affected patients with either HF with reduced ejection fraction (HFrEF) 6 or HF with preserved ejection fraction (HFpEF). 7 These findings have recently been confirmed by independent groups of workers. 8 Sarcopenia and cachexia, besides some overlap in definitions, are different clinical concepts, because only cachexia requires weight loss, whereas patients with sarcopenia may have lost weight, but this characteristic is not a prerequisite of sarcopenia. 9 It is important to understand that sarcopenia means muscle wasting and thus the loss of muscle mass and strength. Such loss implies loss in QoL. 10 As shown by Fülster et al. 6 using data from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF), sarcopenia is a frequent co-morbidity among patients with HF. It leads to lower muscle strength and lower exercise capacity as assessed using the 6-minute walk test (6MWT) and peak oxygen uptake (VO 2 ) on spiroergometry. Similar prevalence values around 20% have been observed in HFrEF or HFpEF patients. 6, 7 A recent study by Yang et al. 11 showed that muscle wasting is a predictor of hospital readmission and long-term mortality in elderly patients in acute care wards.
The aim of the present study was to compare the impact of changes in body composition as exemplified by patients who have cachexia and/or sarcopenia with patients without such changes. For this purpose, we examined effects on exercise capacity and QoL using cross-sectional data from the SICA-HF study.
Methods

Study population
A total of 207 male ambulatory patients were prospectively enrolled as part of SICA-HF at the Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany. Recruitment was commenced in March 2010, and we included all subjects who were recruited until April 2012. All subjects provided written informed consent at enrolment, and the local ethics committee approved the protocol. The study was funded by the European Commission's 7th Framework program (FP7/2007-2013) under grant agreement number 241558 and fulfils all principles of the Declaration of Helsinki. 6 The study protocol has been published previously 12 as has the description of sarcopenia and its clinical implications in HFrEF as well as in HFpEF patients. 6 duration, age >18 years, clinical signs and symptoms of chronic HF with a left ventricular ejection fraction (LVEF) ≤40% (HFrEF) or with an LVEF > 40% and a left atrial diameter ≥40 mm (HFpEF). Patients with previous heart transplantation, cardiac or embolic events within 6 weeks prior to the baseline examination, and patients on haemodialysis, or with known pregnancy were excluded. Chronic kidney disease was defined as a glomerular filtration rate (GFR) <60 mL/min/1.73 m 2 for ≥ 3 months, with or without kidney damage. 13 Before inclusion, patients had to undergo two-dimensional transthoracic echocardiography to assess LVEF (Simpson's biplane technique) and other standard cardiac parameters.
Dual energy X-ray absorptiometry (DEXA) was used to evaluate body composition. DEXA measures total lean mass, and fat mass as a whole or in pre-specified body regions. Appendicular lean mass was defined as the lean mass of both arms and legs combined. Quadriceps strength was assessed using an isokinetic dynamometer (Multitrace 2, Lectromed, Jersey, Channel Islands). The maximal strength was measured in both legs in a sitting position with the patient's legs hanging freely, the ankle fixed by a pressure transducer. The best of three measurements was used. 6 Handgrip strength was analysed using the handgrip dynamometer (Hydraulic Hand Dynamometer, model SH5001, Saehan Corporation, Korea). Likewise, the best of three measurements was used. 6 In addition, all patients underwent treadmill performance testing according to the modified Bruce protocol on a treadmill spiroergometer. 14 Ventilation gases, such as VO 2 (in mL), carbon dioxide production (VCO 2 in mL), peak VO 2 (in mL/min), and anaerobic threshold were recorded. A 6MWT was performed according to standard protocol. 15 The Short Physical Performance Battery (SPPB) score was calculated using the balance test, the gait speed test and the chair stand test with 12 points indicating the highest achievable value. 16 QoL was assessed using the EuroQol-5 Dimensions (EQ-5D) questionnaire and calculating the EQ-5D index score, in which lower results demonstrate lower QoL. 17 Sarcopenia was defined as a muscle mass 2 standard deviation (SD) below the mean of a healthy young reference group aged 18-40 years [appendicular skeletal muscle index (ASMI) <7.26 kg/m 2 for male patients].
18 Lean mass data from DEXA scan were evaluated and ASMI of patients was calculated. This index assesses the appendicular skeletal muscle mass (ASM) in kilograms, calculated as the lean muscle mass of both arms and legs divided by the height (in m) squared. Cachexia was defined as the presence of non-oedematous, non-intentional weight loss of ≥ 6% over a period of at least 1 year as per previously published definition.
19 Using these criteria, we divided patients into four groups according to body composition status: (i) patients with sarcopenia without cachexia (sarcopenic HF group), (ii) patients with cachexia without sarcopenia (cachectic HF group), (iii) patients with cachexia and sarcopenia (sarcopenia + cachexia group), and (iv) patients with neither type of wasting (no wasting group) ( Table 1) . 
13.6 ± 1.5 13.7 ± 1.5 13. ACE-I, angiotensin-converting enzyme inhibitor; AT 1 , angiotensin II type 1 receptor; BMI, body mass index; CKD, chronic kidney disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hsCRP, high-sensitivity C-reactive protein; IL-1, interleukin-1; IL-6, interleukin-6; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; TNF, tumour necrosis factor. § vs. no wasting group; † vs. sarcopenic HF group; * vs. cachectic HF group. Each symbol denotes P < 0.05. Symbols in brackets denote a trend with P < 0.1.
body mass index (BMI) and New York Heart Association (NYHA) classification.
Results
Clinical characteristics
We Figure 1) . In general, patients with sarcopenia had lower strength and exercise capacity than both the no wasting and the cachectic HF group. In detail, handgrip strength, peak VO 2 , distance walked in the 6MWT, SPPB score, and EQ-5D index score results were lowest in the sarcopenia + cachexia group, with significant differences compared to the no wasting group (all P < 0.05, Table 2 and Figure 1 Prevalence of wasting according to the four groups of the study cohort. HF, heart failure. Figure 2) . Besides, the sarcopenia + cachexia group had the lowest values in quadriceps strength in comparison to the other three groups (all P < 0.05, Table 2 and Figure 2) . Likewise, the sarcopenic HF group showed lower handgrip strength, quadriceps strength, 6MWT, peak VO 2 , SPPB score and EQ-5D index score results, with significant differences compared to the no wasting group (all P < 0.05, Table 2 and Figure 2 ). The sarcopenic HF group had the highest age with significant differences compared to both the no wasting group and the cachectic HF group (both P < 0.05, Table 1 ). The sarcopenia + cachexia group had the lowest BMI as compared to both the no wasting group and the cachectic HF group (both P < 0.05, Table 1 ). The sarcopenia + cachexia group showed lower haemoglobin and higher interleukin-6 (IL-6) levels, as compared with the no wasting group (both P < 0.05, 
Body composition
Body composition analysis revealed that total fat was lower in the sarcopenia + cachexia group, with significant differences compared to both the no wasting group and the sarcopenic HF group (both P < 0.05, Table 3 ). Trunk fat was also significantly lower in the sarcopenia + cachexia group as compared to the three other groups (all P < 0.05, Table 3 ). Total lean mass was significantly lower in both the sarcopenia + cachexia and the sarcopenic HF groups with significant differences compared to the cachectic HF group and the no wasting group (both P < 0.05, Table 3 ). oxygen uptake (VO 2 ) in the four study groups. HF, heart failure. § vs. no wasting group; † vs. sarcopenic HF group; *vs. cachectic HF group. One symbol denotes P < 0.05, two symbols P < 0.01, three symbols P < 0.001. Symbols in brackets denote a trend with P < 0.1.
Alternative analyses
It remains unclear whether patients in the sarcopenia + cachexia group should be best grouped together with patients in the cachectic HF or the sarcopenic HF group. We therefore designed two alternative analyses that embrace the two ideas. First, we re-grouped patients from the sarcopenia + cachexia group into the cachectic HF group (both named the cachexia group). Clinical results from this new group were compared with the sarcopenic HF group and the no wasting group ( Table 4) . The new cachexia group had only lower significant results for quadriceps strength and peak VO 2 , as compared to the no wasting group (both P < 0.05, Table 4 ). Considerably, the sarcopenic HF group showed significantly lower handgrip strength, distance walked in the 6MWT, peak VO 2 , SPPB score and EQ-5D index score, as compared to the no wasting group (all P < 0.05, (both named muscle wasting group) and compared them with the cachectic HF group and the no wasting group. The muscle wasting group showed significant lower handgrip strength, quadriceps strength, distance walked in the 6MWT, peak VO 2 , SPPB score and EQ-5D index score as compared to the no wasting group (all P < 0.05, Table 5 ). The cachectic HF group showed only lower significant results for peak VO 2 as compared to the no wasting group (P < 0.05, Table 5 ). EQ-5D index score was significantly lower in the muscle wasting group as compared to both the cachectic HF group and the no wasting group (both P < 0.05, Table 5 ).
Discussion
By definition of subgroups of wasting, we found that 18.8% of patients fulfilled the criteria of cachexia, and 21.3% of patients fulfilled the criteria of sarcopenia; 6.7% of patients fulfilled both criteria, underlining the overlap in the two clinical syndromes. EQ-5D, EuroQol-5 Dimensions; HF, heart failure; 6MWT, 6-minute walk test; SPPB, Short Physical Performance Battery; VO 2 , oxygen uptake. All functional analyses have been adjusted for body mass index, age, and New York Heart Association class, as these were the only significant confounders. § vs. no wasting group; * vs. cachexia group. Each symbol denotes P < 0.05. Symbols in brackets denote a trend with P < 0.1.
Lowest values in muscle strength and muscle function as assessed by measurement of handgrip strength, quadriceps strength, the distance walked in the 6MWT, peak VO 2 , and SPPB score were observed in those groups with sarcopenia being present, but not in the groups not affected by muscle wasting. Likewise, the lowest values in QoL were found in patients affected by muscle wasting, but not in the cachectic HF group. This effect became most apparent when the sarcopenic HF and the sarcopenia + cachexia groups were combined, but was less pronounced after combining the cachectic HF and the sarcopenia + cachexia groups (Tables 4  and 5 ).
Previous studies
About 20 years ago, cachexia had been identified as an independent risk factor for death among ambulatory patients with HF, an effect that has so far not been confirmed in patients with sarcopenic HF. this effect is also present in patients with cachectic HF, it is less pronounced than among patients with sarcopenic HF. One of the reasons for these divergent findings is that skeletal muscle can be affected in cachectic patients, but this is not a necessity, because weight loss can also become manifest by loss of adipose tissue. On the other hand, cachectic patients as well as patients without any wasting tend to present with a considerably higher BMI than patients with sarcopenia. Although obesity is an independent risk factor for developing HF, it has been shown to be paradoxically associated with lower mortality after HF establishment. 20 In fact, current European Society of Cardiology (ESC) guidelines for the management of HF state that in patients with HF with moderate degrees of obesity (BMI <35 kg/m 2 ), weight loss cannot be recommended. In more advanced obesity (BMI 35-45 kg/m 2 ), weight loss may be considered to manage symptoms and exercise capacity. 21 Muscle wasting has been observed in various chronic diseases such as chronic kidney disease, chronic obstructive pulmonary disease, type 2 diabetes. 22 -25 In this context, it has been recognized that the presence of muscle wasting increases the risk of losing physical independence in later life. 26 This fact brings us back to the importance of blunting the deterioration of muscle wasting in patients with chronic HF. Our data are in agreement with previous reports with regard to the prevalence of wasting, even though the numbers are comparatively high. However, research into sarcopenia has only just started in the field of HF, and sarcopenia has been added to the guidelines as a relevant co-morbidity of HF only in the 2016 version of the ESC guidelines. 21 In a prospective study in 55 patients under the age of 55 years with non-ischaemic dilated cardiomyopathy, Hajahmadi et al. 8 studied muscle wasting using the criteria of sarcopenia. In their study, muscle wasting was present in 26 of 55 (47.3%) patients. The prevalence of muscle wasting in this study was even higher than that found in our study (21.3%). Several reasons may account for this. First, the analysis was restricted to HFrEF patients and dilated cardiomyopathy; second, the patients' age was considerably lower than that of our study population. However, Hajahmadi et al. found a very high prevalence of sarcopenia, buttressing the importance of this co-morbidity, also showing significantly lower 6MWT results in the muscle wasting group, which is in agreement with the sarcopenia + cachexia and sarcopenic HF groups' results in our analysis. It is interesting to note that in our present population with an average age of 67.3 ± 10.1 years, the prevalence of sarcopenia reached 21.3%, much higher than expected for subjects of this age group without HF. 27 However, the study by Hajahmadi et al. included patients with an average age of 37.3 ± 10.1 years. Therefore, it appears that HF not only accelerates the progression of ageing-associated sarcopenia, but also develops at a very early stage of the disease.
Anker et al. 5 in their study of 171 patients with chronic HF, showed lower values for peak VO 2 among patients with cachexia vs. patients without cachexia. In our study, all the three sarcopenia + cachexia group, sarcopenic HF group and cachectic HF group showed lower peak VO 2 results than the no wasting group in a similar manner. Such lower exercise capacity among patients with sarcopenic HF has been discussed before within the framework of SICA-HF. 6 The first of these studies that partly analysed data from the same patients as the present study found that muscle wasting was present in 19.5% of 200 patients. 6 In this analysis, . . patients with muscle wasting likewise presented with lower handgrip strength, peak VO 2 and lower distance walked in the 6MWT. However, this study did not discuss cachexia and did not exclude females.
Limitations
Our study has limitations, particularly with regard to the exclusion of females. The number of female patients with cachexia or muscle wasting or both at the same time was very small in our cohort. Thus, we decided to exclude females from the present analysis. Future studies need to explore wasting exclusively in females.
Clinical implications
Strengthening muscle mass and function appears to be an interesting topic in patients with HF and wasting. Our results could be of interest for future therapeutic interventions, which aim to prevent the deterioration of functional capacity in patients with HF. Such interventions likely include exercise training, nutritional support, and drug therapies.
Conclusions
Muscle wasting in elderly subjects has been associated with increasing hospitalization and mortality rates. 28 Our analysis could thus raise a flag that in such a progressive limiting disease like HF, sarcopenia with or without cachexia is associated with poor functional status and QoL. Both cachexia and sarcopenia appear to be valuable targets for the development of therapies in order to improve physical well-being as exemplified by reduced peak VO 2 . Increasing muscle mass and muscle strength appear to be most important in this regard.
